{
  "id": "5a67a72fb750ff445500000a",
  "type": "yesno",
  "question": "Is propranolol used for treatment of infantile hemangioma?",
  "ideal_answer": "Yes,  propranolol is becoming the treatment of choice for complicated infantile hemangioma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24505868",
    "http://www.ncbi.nlm.nih.gov/pubmed/27813086",
    "http://www.ncbi.nlm.nih.gov/pubmed/27473874",
    "http://www.ncbi.nlm.nih.gov/pubmed/27756073",
    "http://www.ncbi.nlm.nih.gov/pubmed/24557492",
    "http://www.ncbi.nlm.nih.gov/pubmed/21385205",
    "http://www.ncbi.nlm.nih.gov/pubmed/26400030",
    "http://www.ncbi.nlm.nih.gov/pubmed/21853649",
    "http://www.ncbi.nlm.nih.gov/pubmed/20071038",
    "http://www.ncbi.nlm.nih.gov/pubmed/22299307",
    "http://www.ncbi.nlm.nih.gov/pubmed/21115582",
    "http://www.ncbi.nlm.nih.gov/pubmed/27737446",
    "http://www.ncbi.nlm.nih.gov/pubmed/23812512",
    "http://www.ncbi.nlm.nih.gov/pubmed/22503260",
    "http://www.ncbi.nlm.nih.gov/pubmed/21837992",
    "http://www.ncbi.nlm.nih.gov/pubmed/27068061",
    "http://www.ncbi.nlm.nih.gov/pubmed/24346925",
    "http://www.ncbi.nlm.nih.gov/pubmed/25511837"
  ],
  "snippets": [
    {
      "text": "Low-dose propranolol for infantile hemangioma of the head and neck: Analysis of 23 consecutive patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473874",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: More and more infantile hemangiomas (IH) are being treated with propranolol, but the effectiveness, dosage, and treatment course are still in dispute.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Low-dose propranolol appears to be effective and safe for IH, especially for those patients previously treated with corticosteroid and who had no response or severe side-effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27473874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cardiovascular Profile of Propranolol after Multiple Dosing in Infantile Hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756073",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Propranolol is becoming the treatment of choice for complicated infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, propranolol 2 mg/kg of body weight daily causes a statistically though not clinically relevant decrease in blood pressure and heart rate in cardially healthy infants affected by infantile hemangioma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance: Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737446",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Infantile hemangiomas (IHs) are the most common benign vascular tumors of childhood. Propranolol is an effective drug in treating IH. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813086",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813086",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION: Ultrasonographic measurements contribute to demonstrate tumor regression and IH response to propranolol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813086",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21115582",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We conclude that the initial use of propranolol as the sole treatment for infantile airway hemangioma is promising.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20071038",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol has been proposed for the treatment of infantile hemangiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24505868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol therapy is changing the treatment paradigm for infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24557492",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol has been successfully used recently in a limited number of children with Infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346925",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol has been proposed for the treatment of infantile hemangiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24505868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS This is the first report of successful therapy of an intracranial infantile hemangioma with propranolol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27068061",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE The successful use of nadolol as an alternative to propranolol therapy in three cases of infantile hemangioma is reported.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25511837",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol has been used successfully in a limited number of children with infantile hemangiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS High-dose Propranolol is very effective in the treatment of infantile hemangioma with minor side effects and short disease period.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21837992",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol is novel and safe medication for treatment of infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22299307",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol is the only Food and Drug Administration approved therapy for treatment of patients with this vascular anomaly and should be considered first-line therapy for genital infantile hemangiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26400030",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION Propranolol may be a promising therapeutic modality for infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22503260",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol, which is often used to treat cutaneous infantile hemangiomas, is not currently standard treatment for intracranial infantile hemangiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27068061",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Preliminary results of propranolol treatment for patients with infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21853649",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Propranolol therapy is changing the treatment paradigm for infantile hemangioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24557492",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol should be considered as a first-line treatment of infantile hemangiomas..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23812512",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Propranolol, a non-selective beta-blocker, has recently been introduced as a treatment for infantile hemangiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21853649",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D006391",
    "https://meshb.nlm.nih.gov/record/ui?ui=D013812",
    "http://www.biosemantics.org/jochem#4275197",
    "https://meshb.nlm.nih.gov/record/ui?ui=D011433"
  ],
  "exact_answer": "Yes"
}